CASR (Calcium Sensing Receptor) Drug Discovery Landscape & Assay Solutions
- By admin
- 18 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Hyperparathyroidism and Bone Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CASR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CASR ECD-Fc Fusion Protein (AA 20-612), HEK293 Expressed. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. | View CASR Products |
| Gene Delivery | CASR Lentivirus Premade Particles (Full-length ORF NM_000388) for stable cell line generation. CMV promoter, Puromycin resistance. | View CASR Products |
| Benchmark Ab | Anti-CASR Reference Antibody (Clone 1C11). Recombinant monoclonal for positive control in flow cytometry and Western blot. | View CASR Products |
| Validator | CASR siRNA Set (3 pre-designed siRNAs) for knockdown verification in calcium flux assays. Sequence verified, high purity. | View CASR Products |
| Related Target A | PTH (Parathyroid Hormone). Downstream hormone regulated by CASR activation. | View PTH Products |
| Related Target B | PTH1R (Parathyroid Hormone Receptor 1). Synergistic pathway for calcium homeostasis. | View PTH1R Products |
| Related Target C | GPRC6A. Family C GPCR; Critical for off-target selectivity screening (calcium/amino acid sensing). | View GPRC6A Products |
| Related Target D | CASR (R185Q Mutant). Familial Hypocalciuric Hypercalcemia (FHH) variant; Loss-of-function mechanism study. | View CASR R185Q Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | Lentivirus-based stable cell lines preserving native glycosylation and signaling (HEK293 background). |
| Cross-species Toxicology (Cyno/Mouse) | Human, Cyno, Mouse ortholog lentivirus & protein available; Sequence verified homology >90%. |
| Off-target Risk (GPRC6A/GRM1) | Homolog panel (GPRC6A, GRM1) for selectivity screening; Strict mass spec verification. |
| Allosteric Binding Site Validation | Full-length CASR cell lines with intact ECD-TM interface for modulator studies. |
| Lack of Controls | Benchmark Antibodies included. |
| False Positives | Validated siRNA included for specificity checks in calcium mobilization assays. |
Live CASR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CASR therapeutics is intensifying, with major players shifting focus from traditional small molecules (calcimimetics) to novel allosteric modulators and biologics. As first-generation therapies for hyperparathyroidism reach maturity, the next wave of R&D is targeting calcilytics for osteoporosis and hypocalcemia, requiring precise conformational targeting of this complex Class C GPCR. The pipeline bifurcates into positive modulators (hyperparathyroidism) and negative modulators (hypoparathyroidism/autosomal dominant hypocalcemia), demanding nuanced assay systems capable of discriminating biased signaling and species-specific pharmacology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Positive Allosteric Modulator (Calcimimetic) | Amgen, Kyowa Kirin | Secondary Hyperparathyroidism (SHPT), Primary Hyperparathyroidism | Calcium Flux & β-arrestin assays (Need stable full-length CASR cell lines) |
| Negative Allosteric Modulator (Calcilytic) | BridgeBio, Novartis | Autosomal Dominant Hypocalcemia (ADH), Hypoparathyroidism | Inverse agonist assays; Mutant CASR (ADH variants) validation |
| Peptide Mimetic | Kyowa Kirin | SHPT (IV administration) | Receptor internalization assays (Need high-expression lentivirus) |
| Monoclonal Antibody / Biologic | Various Biotech, Preclinical | Hypocalcemia, Calciphylaxis, Hypercalcemia of Malignancy | ECD binding & internalization (Need high-purity ECD-Fc protein) |